There is an urgent need to assess country experiences and evidence that address the preferences among Options A, B and B+ outlined here. Evidence on the operational advantages of providing triple ARVs to all HIV-infected pregnant women (Options B and B+), on how to best meet the programme requirements of these approaches, and on the acceptability, effectiveness and prevention impact of providing lifelong ART to all HIV-infected pregnant women (Option B+) will help inform upcoming guidelines revision. This programmatic update is meant to provide a current perspective for countries on the important changes and new considerations arising since the 2010 PMTCT ARV guidelines, especially as a number of countries are now preparing.
